London (United Kingdom) – Stallergenes Greer plc (the “Company”) (Euronext Paris: STAGR), a biopharmaceutical company specializing in treatments for respiratory allergies, today announced that it has been authorized to restart the manufacturing of its Named Patient Products (NPP) after a temporary suspension at its Stallergenes SAS plant in Antony, France. NPP products, such as STALORAL® will be progressively available again to our patients.
This temporary suspension was enacted following observations made by the French Health Authority (ANSM), regarding the implementation of a new IT system. The launch of this IT system, aimed at providing upgraded supply and delivery of Stallergenes Greer’s products, resulted in operational disruptions that have now been fully addressed. This suspension lift enables Stallergenes Greer to fully resume its activities, according to a progressive restart plan.
“We are very pleased with the resumption of NPP production, notably STALORAL® which has been the most prescribed sublingual allergy immunotherapy worldwide,” said Fereydoun Firouz, Chairman and Chief Executive Officer of Stallergenes Greer. “The temporary suspension was the result of issues with the IT interfaces which are now fully resolved. With a fully operational ERP system now in place, Stallergenes Greer is setting the stage for a transformative business culture. We have emerged from this technical challenge stronger as an organization, wiser and more determined than ever to realize our long-term curative ambitions for our patients.”